CD274 and cancer: In recent years, owing to the emergence of novel immunotherapy strategies involving PD-1 and PD-L1 and the clinical efficacy of PD-1 and PD-L1 blockade in various solid cancers, blocking of the PD-1 and PD-L1 pathways has emerged as an effective strategy for cancer treatment [15, 16].